15:49 30/07/2015 Biotech Stocks: Here's Where to Get In: Arena Pharmaceuticals, Inc. (NASDAQ ...
Biotech Stocks: Here's Where to Get In: Arena Pharmaceuticals, Inc. (NASDAQ ...
Wall Street Point - 12 hours ago
On the trading floor, shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) gained 0.25% to close at $4.09. The company on July 29, 2015 declared recently the initiation of patient screening in a Phase 2 proof-of-concept clinical trial of APD334 in ...

13:00 30/07/2015 Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and ...
Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and ...
PR Newswire (press release) - 15 hours ago
SAN DIEGO, July 30, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 5:00 p.m.

12:48 30/07/2015 Zacks Rating on Arena Pharmaceuticals, Inc.
Zacks Rating on Arena Pharmaceuticals, Inc.
Money Flow Index - 15 hours ago
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a hold, according to the latest average broker rating of 2.5. The number of analysts in this rating is 6. Research Analysts at Zacks has the shares a rating of 3, which implies that the firms recommendation ...
Arena Pharmaceuticals Receives Consensus Recommendation of "Hold" from ... - Dakota Financial News
Morning Eye-Catchers: Arena Pharmaceuticals, Inc. (ARNA), CenturyLink, Inc ... - WallStreet Scope

11:42 30/07/2015 Biotech Stocks Worth Chasing - Amicus Therapeutics, Inc. (NASDAQ:FOLD), Arena ...
Biotech Stocks Worth Chasing - Amicus Therapeutics, Inc. (NASDAQ:FOLD), Arena ...
Wall Street Observer - 16 hours ago
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rose +0.25% to end last trading session at $4.09. The company, on July 29, 2015, released the initiation of patient screening in a Phase 2 proof-of-concept clinical trial of APD334 in ulcerative colitis ...

5:48 30/07/2015 Small Cap VIVUS, Inc (VVUS) Earnings Report: Continued Weight Loss? ARNA, ETRM ...
Small Cap VIVUS, Inc (VVUS) Earnings Report: Continued Weight Loss? ARNA, ETRM ...
SmallCap Network - 22 hours ago
The Q2 2015 earnings report for small cap obesity stock VIVUS, Inc (NASDAQ: VVUS), who's potential obesity treatment peers include Arena Pharmaceuticals, Inc (NASDAQ: ARNA), EnteroMedics Inc (NASDAQ: ETRM) and Orexigen Therapeutics, Inc ...

19:00 29/07/2015 Arena's Phase 2 Trial An Opportunity For Improved Valuation (ARNA)
Arena's Phase 2 Trial An Opportunity For Improved Valuation (ARNA)
Seeking Alpha - Jul 29, 2015
Arena Pharmaceuticals (NASDAQ:ARNA) announced today that the company is moving forward with a Phase 2 clinical trial on its drug candidate called APD334.

13:20 29/07/2015 12-Month Top Losers in Healthcare: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
12-Month Top Losers in Healthcare: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Wall Street Observer - Jul 29, 2015
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), latest closing price of $4.08 is at a discount to its 200-day moving average price of $4.47.

13:00 29/07/2015 Arena Pharmaceuticals Initiates a Phase 2 Clinical Trial of APD334, its S1P1 ...
Arena Pharmaceuticals Initiates a Phase 2 Clinical Trial of APD334, its S1P1 ...
PR Newswire (press release) - Jul 29, 2015
SAN DIEGO, July 29, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of patient screening in a Phase 2 proof-of-concept clinical trial of APD334 in ulcerative colitis.

15:37 28/07/2015 Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Short Interest Update
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Short Interest Update
Insider Trading Report - Jul 28, 2015
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), A drop of 1,185,971 shares or 4% was seen in the short interest of Arena Pharmaceuticals, Inc.. Even as the interest dropped from 29,624,866 shares on June 30,2015 to 28,438,895 shares on July 15,2015, the ...
Stock Update - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Vanguard Tribune

18:15 16/07/2015 Arena Pharmaceuticals (ARNA) Showing Signs Of Perilous Reversal Today
Arena Pharmaceuticals (ARNA) Showing Signs Of Perilous Reversal Today
TheStreet.com - Jul 16, 2015
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Analyst Rating Update - Insider Trading Report
Arena Benefits From Celgene Buyout Of Receptos - Seeking Alpha